Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa

Journal of Psychopharmacology

Volumn 22, Issue 4, 2008, Pages 426-433

  Smarius, L J C A ^a,b   Jacobs, Gabriël E ^a,b   Hoeberechts Lefrandt, D H M ^a   De Kam, M L ^a   Van Der Post, J P ^a   De Rijk, R ^c   Van Pelt, J ^b   Schoemaker, R C ^a   Zitman, F G ^a,b   Van Gerven, J M A ^a   Gijsman, H J ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

5 HT; 5 HTP; Challenge test; Cortisol; HPA axis; Pharmacodynamics; Pharmacokinetics; Prolactin; Serotonergic function; Side effects

Indexed keywords

5 HYDROXYTRYPTOPHAN; ANTIDEPRESSANT AGENT; CARBIDOPA; CORTICOTROPIN; ENZYME INHIBITOR; HYDROCORTISONE; PROLACTIN;

ADULT; AFFECT; ARTICLE; BIOAVAILABILITY; BLOOD; BRAIN; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENTIATION; HALF LIFE TIME; HUMAN; MALE; METABOLIC CLEARANCE RATE; METABOLISM; NAUSEA; ORAL DRUG ADMINISTRATION; PATIENT; RANDOMIZED CONTROLLED TRIAL; STATISTICS; VOMITING;

5-HYDROXYTRYPTOPHAN; ADMINISTRATION, ORAL; ADRENOCORTICOTROPIC HORMONE; ADULT; AFFECT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIOLOGICAL AVAILABILITY; BRAIN; CARBIDOPA; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG SYNERGISM; ENZYME INHIBITORS; HALF-LIFE; HUMANS; HYDROCORTISONE; MALE; METABOLIC CLEARANCE RATE; NAUSEA; PATIENT DROPOUTS; PROLACTIN; VOMITING; YOUNG ADULT;

EID: 58149120961     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107082025     Document Type: Article

References (28)

1. Arrindell W A, Ettema J H M (1986) SCL-90. Handleiding bij een multidimensionele psychopathologie-indicator. Swets and Zeitlinger, Lisse
2. Birmaher B, Kaufman J, Brent D A, Dahl R E, Perel J M, al Shabbout M, Nelson B, Stull S, Rao U, Waterman G S, Williamson D E, Ryan N D (1997) Neuroendocrine response to 5-hydroxy-L-tryptophan in prepubertal children at high risk of major depressive disorder. Arch Gen Psychiatry 54: 1113-1119 (Pubitemid 27524377)
3. Bond A, Lader M (1974) The use of analogue scale in rating subjective feelings. Br J Med Psychol 47: 211-218
4. den Boer J A, Westenberg H G (1990) Behavioral, neuroendocrine, and biochemical effects of 5-hydroxytryptophan administration in panic disorder. Psychiatry Res 31: 267-278
5. Derogatis L R, Lipman R S, Covi L (1973) SCL-90: an outpatient psychiatric rating scale-preliminary report. Psychopharmacol Bull 9: 13-28
6. Gartside S E, Cowen P J (1990) Mediation of ACTH and prolactin responses to 5-HTP by 5-HT2 receptors. Eur J Pharmacol 179: 103-109 (Pubitemid 20142891)
7. Gijsman H J, Van Gerven J M, Tieleman M C, Schoemaker R C, Pieters M S, Ferrari M D, Cohen A F, Van Kempen G M (1998) Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers. J Clin Psychopharmacol 18: 289-295 (Pubitemid 28353871)
8. Gijsman H J, van Gerven J M A, de Kam M L, Schoemaker R C, Pieters M S M, Weemaes M, de Rijk R, van der Post J, Cohen A F (2002a) Placebo-controlled comparison of three dose-regimens of 5-hydroxytryptophan challenge test in healthy volunteers. J Clin Psychopharmacol 22: 183-189 (Pubitemid 34289393)
9. Gijsman H J, van Gerven J M A, Verkes R J, Schoemaker R C, Pieters M S M, Pennings E J M, Hessing T J, Cohen A F (2002b) Saccadic peak velocity and EEG as end-points for a serotonergic challenge test. Human Psychopharm Clin Exp 17: 83-89 (Pubitemid 34257814)
10. Gijsman H J, Cohen A F, Van Gerven J M (2004) The application of the principles of clinical drug development to pharmacological challenge tests of the serotonergic system. J Psychopharmacol 18: 7-13 (Pubitemid 38623086)
11. Groenestijn M A C, Akkerhuis G W, Kupka R W, Schneider, Nolen W A (1999) Structured clinical interview for DSM-IV axis I disorders. Swets Test, Lisse
12. Imura H, Nakai Y, Yoshimi T (1973) Effect of 5-hydroxytryptophan (5-HTP) on growth hormone and ACTH release in man. J Clin Endocrinol Metab 36: 204-206
13. Jorgensen H, Knigge U, Kjaer A, Moller M, Warberg J (2002) Serotonergic stimulation of corticotropin-releasing hormone and pro-opiomelanocortin gene expression. J Neuroendocrinol 14: 788-795 (Pubitemid 35203476)
14. Lee M A, Nash J F, Barnes M, Meltzer H Y (1991) Inhibitory effect of ritanserin on the 5-hydroxytryptophan-mediated cortisol, ACTH and prolactin secretion in humans. Psychopharmacology (Berl) 103: 258-264
15. Magnussen I, Engbaek F (1978) The effects of aromatic amino acid decarboxylase inhibitors on plasma concentrations of 5-hydroxytryptophan in man. Acta Pharmacol Toxicol (Copenh) 43: 36-42 (Pubitemid 8404438)
16. Magnussen I, Nielsen-Kudsk F (1979) Pharmacokinetics of intravenously administered L-5-hydroxytryptophan in man. Acta Pharmacol Toxicol (Copenh) 44: 308-314 (Pubitemid 9126943)
17. Maron E, Toru I, Vasar V, Shlik J (2004) The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers. J Psychopharmacol 18: 194-199 (Pubitemid 38954906)
18. McNair D M, Lorr M, Droppelman L F (1971) Manual for the profile of mood states. EdITS, San Diego, CA
19. Meibohm B, Derendorf H (1997) Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther 35: 401-413 (Pubitemid 27462583)
20. Norris H (1971) The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology 10: 181-191
21. Ryan N D, Birmaher B, Perel J M, Dahl R E, Meyer V, al Shabbout M, Iyengar S, Puig-Antich J (1992) Neuroendocrine response to L-5-hydroxytryptophan challenge in prepubertal major depression. Depressed vs normal children. Arch Gen Psychiatry 49: 843-851
22. Schruers K, van Diest R, Nicolson N, Griez E (2002a) L-5-hydroxytryptophan induced increase in salivary cortisol in panic disorder patients and healthy volunteers. Psychopharmacology (Berl) 161: 365-369 (Pubitemid 34595787)
23. Schruers K, van Diest R, Overbeek T, Griez E (2002b) Acute L-5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients. Psychiatry Res 113: 237-243 (Pubitemid 36136046)
24. Spielberger C D, Gorsuch R L, Lushene R E (1983) STAI manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, Palo Alto, CA
25. van Vliet I M, Slaap B R, Westenberg H G, den Boer J A (1996) Behavioral, neuroendocrine and biochemical effects of different doses of 5-HTP in panic disorder. Eur Neuropsychopharmacol 6: 103-110 (Pubitemid 26183596)
26. Vlasses P H, Rotmensch H H, Swanson B N, Clementi R A, Ferguson R K (1989) Effect of repeated doses of L-5-hydroxytryptophan and carbidopa on prolactin and aldosterone secretion in man. J Endocrinol Invest 12: 87-91 (Pubitemid 19085796)
27. Wald F D M, Mellenbergh G J (1990) De verkorte versie van de Nederlandse vertaling van de Profile of Mood States (POMS). Ned T Psychol 45: 86-90
28. Westenberg H G, Gerritsen T W, Meijer B A, van Praag H M (1982) Kinetics of l-5-hydroxytryptophan in healthy subjects. Psychiatry Res 7: 373-385 (Pubitemid 13172082)